RESUMO
Cyclooxygenase-2 [COX-2] is over expressed in a variety of premalignant and malignant conditions. It may contribute to carcinogenesis by modulating xenobiotic metabolism, apoptosis, immune surveillance, and angiogenesis. Selective COX-2 inhibitors suppress the formation of tumors in experimental models. Selective COX-2 inhibitors also suppress the growth and metastases of established tumors and enhance the anticancer activity of both radiotherapy and chemotherapy in experimental animals. This review aims at discussing evidence that inhibition of COX-2 represents a promising strategy to treat, prevent or possibly prevent human malignancies. Importantly, selective COX-2 inhibitors do not inhibit platelet function and cause fewer gastrointestinal side effects [peptic ulcer disease] than traditional nonsteroidal anti-inflammatory drugs [NSAIDS]. More clinical trials are warranted to define the role of selective COX-2 inhibitors in the prevention and treatment of cancer along with their assessment of toxicity
Assuntos
Humanos , Inibidores de Ciclo-Oxigenase , Neoplasias do Sistema Digestório/tratamento farmacológico , Neoplasias Pulmonares/tratamento farmacológicoRESUMO
El 5 fluorouracilo es el quimioterápico fundamental en el tratamiento del cáncer digestivo. Para obtener un mejor índice terapéutico, se puede emplear este fármaco en altas dosis (3 gr./m2), asociado a allopurinol, que previene la toxicidad en tejidos normales. En este trabajo se evalúan fundamentalmente los efectos colaterales en 20 pacientes portadores de neplasias avanzadas. Se demuestra la aparición de efectos tóxicos en un nivel aceptable que permite el uso de esta forma de suministrar el fármaco mencionado